Recruiting studies: Egfr Mutant Non Small Cell Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
Phase 1/Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07535437 Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · 604 location(s) · National Cancer Institute (NCI) · NCT04181060 JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
Phase 2 · 2 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT07518160 CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease
NA · 1 location(s) · British Columbia Cancer Agency · NCT05257967 A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
Phase 1/Phase 2 · 10 location(s) · J Ints Bio · NCT05394831 Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06924398 Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
NA · 1 location(s) · Guangzhou University of Traditional Chinese Medicine · NCT07348965 Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT06355609 Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06863506 High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-g
Phase 2 · 1 location(s) · Jialei Wang · NCT06652048 EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT07637448 Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
Phase 2 · 26 location(s) · Sun Yat-sen University · NCT05334277 Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06363734 Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05011487 ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
Phase 2 · 1 location(s) · Fudan University · NCT06775743 Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT05284539 Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor The
Phase 2 · 1 location(s) · Pusan National University Hospital · NCT07073365 Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patie
Phase 1 · 45 location(s) · BioNTech SE · NCT05142189 Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Phase N/A · 1 location(s) · Hunan Province Tumor Hospital · NCT04324164 Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT04780568 Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Phase 2 · 1 location(s) · Samsung Medical Center · NCT06106802 Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
Phase 2 · 16 location(s) · Guangdong Association of Clinical Trials · NCT05536505 AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients
Phase N/A · 1 location(s) · Fudan University · NCT06604689 Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Ca
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT07323056 MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Phase 1 · 1 location(s) · Emory University · NCT04762199 A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-m
Phase N/A · 34 location(s) · Alpha Biopharma (Jiangsu) Co., Ltd. · NCT07143045 Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT05997719 A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Phase 1/Phase 2 · 29 location(s) · Voronoi, Inc · NCT07699328 Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Phase 2 · 18 location(s) · Memorial Sloan Kettering Cancer Center · NCT04410796 Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Phase 1/Phase 2 · 10 location(s) · Genprex, Inc. · NCT04486833

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.